Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors
Daniela Sanges, … , Marta Nicolás, Maria Pia Cosma
Daniela Sanges, … , Marta Nicolás, Maria Pia Cosma
Published July 18, 2016
Citation Information: J Clin Invest. 2016;126(8):3104-3116. https://doi.org/10.1172/JCI85193.
View: Text | PDF
Research Article

Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors

  • Text
  • PDF
Abstract

Vision impairments and blindness caused by retinitis pigmentosa result from severe neurodegeneration that leads to a loss of photoreceptors, the specialized light-sensitive neurons that enable vision. Although the mammalian nervous system is unable to replace neurons lost due to degeneration, therapeutic approaches to reprogram resident glial cells to replace retinal neurons have been proposed. Here, we demonstrate that retinal Müller glia can be reprogrammed in vivo into retinal precursors that then differentiate into photoreceptors. We transplanted hematopoietic stem and progenitor cells (HSPCs) into retinas affected by photoreceptor degeneration and observed spontaneous cell fusion events between Müller glia and the transplanted cells. Activation of Wnt signaling in the transplanted HSPCs enhanced survival and proliferation of Müller-HSPC hybrids as well as their reprogramming into intermediate photoreceptor precursors. This suggests that Wnt signaling drives the reprogrammed cells toward a photoreceptor progenitor fate. Finally, Müller-HSPC hybrids differentiated into photoreceptors. Transplantation of HSPCs with activated Wnt functionally rescued the retinal degeneration phenotype in rd10 mice, a model for inherited retinitis pigmentosa. Together, these results suggest that photoreceptors can be generated by reprogramming Müller glia and that this approach may have potential as a strategy for reversing retinal degeneration.

Authors

Daniela Sanges, Giacoma Simonte, Umberto Di Vicino, Neus Romo, Isabel Pinilla, Marta Nicolás, Maria Pia Cosma

×

Figure 5

Regeneration of photoreceptors in rd10 mice.

Options: View larger image (or click on image) Download as PowerPoint
Regeneration of photoreceptors in rd10 mice.
(A and B) Representative im...
(A and B) Representative immunostainings of YFP+ (green) with either GS (red, white arrow) or recoverin (red, yellow arrows) in rd10R26Y retinas 42 days after transplantation of BIO-treated (A) or untreated (B) HSPCsVav-Cre. n = 3. (C) Total number of YFP+ hybrids (green bars) that incorporated BrdU (red bars) detected in rd10R26Y eyes 24 hours (P19), 72 hours (P21), and 42 days (P60) after transplantation of untreated or BIO-treated HSPCsVav-Cre. Data are represented as mean ± SD. n = 9. **P < 0.001; *P < 0.01, 2-way ANOVA and Bonferroni’s post-test. Red and green lines show the statistical significance of the difference between the respective green (YFP) and red (BrdU) bars. (D) Percentages of double YFP+BrdU+ hybrids also positive for GS, OTX2, or recoverin stainings 42 days (P60) after transplantation of untreated (gray bars) or BIO-treated ( black bars) HSPCsVav-Cre in rd10R26Y retinas. Data are represented as mean ± SD. n = 9. (E) Representative immunodetection of BrdU+ cells (red) also positive for the photoreceptor marker recoverin (green) in the ONL of MNU-damaged rd10R26Y retinas 42 days after transplantation of BIO-treated HSPCsVav-Cre. Nuclei were counterstained with DAPI (blue). Insert shows higher magnification of the region in the white square. (F) Representative confocal image of YFP+ hybrids (green) also positive for BrdU (red) and recoverin (blue) in the ONL of rd10R26Y retinas 42 days after transplantation of BIO-treated HSPCsVav-Cre. Images at the bottom represent enlargements of the same YFP+ hybrid (green) also positive for recoverin (blue in the left panel) and for BrdU (red in the right panel) stainings. n = 3. Scale bar: 20 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts